Featured Research

from universities, journals, and other organizations

Gene Associated With Breast Cancer May Play Major Role In Prostate Cancer Recurrence

Date:
May 12, 2005
Source:
University Of North Carolina School Of Medicine
Summary:
A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

CHAPEL HILL -- A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

The most common cancer in men, prostate cancer can be effectively treated with surgery or radiation when detected early. But advanced prostate cancer is usually treated by drugs or surgery aimed at reducing the level of testosterone and other male hormones, or androgens, that stimulate cancer cell growth. While the disease usually regresses after such treatment, prostate cancer invariably comes back, although it's not clear why it recurs and progresses.

The UNC study, published April 15 in the journal Cancer Research, indicates that the gene HER-2 is a key culprit in prostate cancer recurrence. The findings also suggest a new treatment strategy for targeting HER-2 in patients with advanced prostate cancer.

HER-2 refers to human epidermal growth factor receptor 2. The gene helps control how cells grow, divide and repair themselves, and directs the production of a special protein called HER-2 tyrosine kinase. This protein acts as receptors on the cell membrane, and when activated by external hormones, it promotes cell growth and division.

In about one in four breast cancers, a genetic mutation creates too many HER-2 receptors. This helps spur rapid cancer cell growth. While treatment with the antibody drug Herceptin can be effective in slowing breast cancer growth, this is not the case in prostate cancer, researchers said.

"The treatment with the antibody has been a uniform failure in prostate cancer because the gene is not over-expressed in this disease. We need a different approach to attack HER-2 in prostate cancer," said the study's senior author, Dr. Young Whang. He is an assistant professor of medicine and medical oncologist at UNC and a member of UNC Lineberger.

"We believe that the driving force for recurrence of prostate cancer is the reactivation of the androgen receptor, which normally requires the presence of androgen, and this reactivation of the androgen receptor underlies tumor progression of prostate cancer despite hormonal therapy. Exactly how this occurs, we're not sure, but our hypothesis is that activation of HER-2 tyrosine kinase leads to activation of the androgen receptor."

In testing their hypothesis, Whang and his co-authors inhibited HER-2 activity in two laboratory experiments involving human cancer cells. In the first, they used an artificial antibody to HER-2 delivered directly into the cells via a modified virus. In the second, they used an experimental drug that specifically inhibits HER-2 tyrosine kinase activity. The oral drug lapatinib (GlaxoSmithKline) is currently in an advanced clinical trial involving patients whose breast cancer is driven by HER-2.

In both experiments, tyrosine kinase activity and androgen receptor function were largely derailed.

"We discovered that inhibition of HER-2 strongly inhibits proliferation of prostate cancer cells and the function of androgen receptor," Whang said.

To properly carry out its function, the androgen receptor protein binds specifically to the regulatory DNA sequence of the genes regulated by androgens such as testosterone, he said. "And we have shown that inhibition of HER-2 impairs the androgen receptor function at this step of binding to the DNA sequence of critical genes such as prostate specific antigen."

The implication of this work, he added, is that HER-2 is important and necessary for prostate cancer viability and progression.

"This provides the rationale for initiating a clinical trial of this novel drug inhibiting HER-2, which is being planned for patients within several months," Whang said. "I envision this drug becoming one of several that could be used in combination with other specifically targeted drugs to prolong the lives of prostate cancer patients."

UNC co-authors with Whang include postdoctoral researchers Drs. Yuanbo Liu and Samarpan Majumder; Wesley McCall, research technician; Dr. Carolyn Sartor, assistant professor of radiation oncology; Dr. James Mohler, professor of surgery; and Dr. Shelton Earp, director, UNC Lineberger. Dr. Christopher Gregory, former UNC assistant professor of pathology and another co-author, is now with Voyager Pharmaceutical Corp. in Raleigh.

The research was supported by grants from the U.S. Army Medical Research and Materiel Command and the National Cancer Institute, a component of the National Institutes of Health.


Story Source:

The above story is based on materials provided by University Of North Carolina School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina School Of Medicine. "Gene Associated With Breast Cancer May Play Major Role In Prostate Cancer Recurrence." ScienceDaily. ScienceDaily, 12 May 2005. <www.sciencedaily.com/releases/2005/05/050512102304.htm>.
University Of North Carolina School Of Medicine. (2005, May 12). Gene Associated With Breast Cancer May Play Major Role In Prostate Cancer Recurrence. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2005/05/050512102304.htm
University Of North Carolina School Of Medicine. "Gene Associated With Breast Cancer May Play Major Role In Prostate Cancer Recurrence." ScienceDaily. www.sciencedaily.com/releases/2005/05/050512102304.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
101-Year-Old Working Man Has All The Advice You Need

101-Year-Old Working Man Has All The Advice You Need

Newsy (Aug. 19, 2014) Herman Goldman has worked at the same lighting store for almost 75 years. Find out his secrets to a happy, productive life. Video provided by Newsy
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
American Ebola Patient Apparently Improving, Outbreak Is Not

American Ebola Patient Apparently Improving, Outbreak Is Not

Newsy (Aug. 19, 2014) Nancy Writebol, an American missionary who contracted Ebola, is apparently getting better, according to her husband. The outbreak, however, is not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins